MedTrace Logo

Lenvatinib in Combination With Carboplatin Pemetrexed and Pembrolizumab for NSCLC With EGFR Mutations

NCT05258279 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2024-08-28

No results posted yet for this study

Summary

The purpose of this study is to assess the safety and efficacy of pemetrexed + carboplatin + pembrolizumab (MK-3475) with lenvatinib (MK-7902/E7080) in patients with advanced nonsquamous non-small cell lung cancer harboring EGFR mutations.

Conditions

  • Non-squamous Non-small-cell Lung Cancer
  • EGFR Activating Mutation

Interventions

DRUG

Pembrolizumab

IV infusion Q3W

DRUG

Lenvatinib

Oral capsule once daily

DRUG

Carboplatin

IV infusion Q3W

DRUG

Pemetrexed

IV infusion Q3W

Sponsors & Collaborators

Principal Investigators

  • Ryo Ko, MD, PhD · Department of Respiratory Medicine, Juntendo University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-07-01
Primary Completion
2023-10-31
Completion
2024-10-31
FDA Drug
Yes

Countries

  • Japan

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05258279 on ClinicalTrials.gov